近岸蛋白：2024年第一季度净利润亏损263.05万元

金融界04-28

近岸蛋白公告称，2024年第一季度，公司实现营业收入26,087,054.66元，较上年同期下降39.34%；归属于上市公司股东的净利润亏损2,630,474.68元，同比下降123.61%；归属于上市公司股东的扣除非经常性损益的净利润为亏损1,170,6041.48元，同比下降273.62%。经营活动产生的现金流量净额为7,558,148.81元，同比下降68.17%。基本每股收益为-0.04元...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2430382880?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-28 16:26","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2430382880","market":"sh","top_or_hot":-1,"title":"近岸蛋白：2024年第一季度净利润亏损263.05万元","media":"金融界","content":"<div>\n<p>近岸蛋白公告称，2024年第一季度，公司实现营业收入26,087,054.66元，较上年同期下降39.34%；归属于上市公司股东的净利润亏损2,630,474.68元，同比下降123.61%；归属于上市公司股东的扣除非经常性损益的净利润为亏损1,170,6041.48元，同比下降273.62%。经营活动产生的现金流量净额为7,558,148.81元，同比下降68.17%。基本每股收益为-0.04元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042816273687ba0c6a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>近岸蛋白：2024年第一季度净利润亏损263.05万元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n近岸蛋白：2024年第一季度净利润亏损263.05万元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-28 16:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042816273687ba0c6a&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近岸蛋白公告称，2024年第一季度，公司实现营业收入26,087,054.66元，较上年同期下降39.34%；归属于上市公司股东的净利润亏损2,630,474.68元，同比下降123.61%；归属于上市公司股东的扣除非经常性损益的净利润为亏损1,170,6041.48元，同比下降273.62%。经营活动产生的现金流量净额为7,558,148.81元，同比下降68.17%。基本每股收益为-0.04元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042816273687ba0c6a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688137","symbol_name":"近岸蛋白","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042816273687ba0c6a&s=b","article_id":"2430382880","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042816273687ba0c6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2430382880","pubTimestamp":1714292799,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近岸蛋白公告称，2024年第一季度，公司实现营业收入26,087,054.66元，较上年同期下降39.34%；归属于上市公司股东的净利润亏损2,630,474.68元，同比下降123.61%；归属于上市公司股东的扣除非经常性损益的净利润为亏损1,170,6041.48元，同比下降273.62%。经营活动产生的现金流量净额为7,558,148.81元，同比下降68.17%。同时，公司持续在mRNA疫苗药物、生物药、体外诊断、生命科学基础研究等领域维持较高水平的研发投入，本报告期研发费用支出为1,100.08万元，确保公司技术优势。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"688137":"近岸蛋白"},"translate_title":"Nearshore protein: net profit loss of 2.6305 million yuan in the first quarter of 2024","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688137":1},"content_text":"近岸蛋白公告称，2024年第一季度，公司实现营业收入26,087,054.66元，较上年同期下降39.34%；归属于上市公司股东的净利润亏损2,630,474.68元，同比下降123.61%；归属于上市公司股东的扣除非经常性损益的净利润为亏损1,170,6041.48元，同比下降273.62%。经营活动产生的现金流量净额为7,558,148.81元，同比下降68.17%。基本每股收益为-0.04元，同比下降125.00%。报告期内，公司营业收入及净利润的下降主要是由于国内生物医药市场环境的阶段性调整和行业波动，常规业务增速减缓，产品销售结构发生较大变化，以及mRNA原料酶及试剂在非新冠类传染病疫苗、肿瘤疫苗、抗体/蛋白替代等领域的需求尚未放量。此外，公司为增强业务拓展，扩充营销团队，积极推进海外市场运营，增强品牌建设和客户覆盖率，导致销售费用较上年同期有所增加。同时，公司持续在mRNA疫苗药物、生物药、体外诊断、生命科学基础研究等领域维持较高水平的研发投入，本报告期研发费用支出为1,100.08万元，确保公司技术优势。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430382880"}